Raltegravir in HIV-1 Infection: Safety and Efficacy in Treatment-naïve Patients

Overview

Journal Clin Med Rev Ther

Publisher Sage Publications

Date 2012 Mar 6

PMID 22389581

Citations 7

Authors

Krishan K Pandey

Affiliations

Soon will be listed here.

Abstract

The hunt for a compound which inhibits the HIV-1 integrase had been painstakingly difficult. Integrase is essential for viral replication as it mediates the integration of the viral DNA genome into the host DNA resulting in the establishment of the permanent provirus. Persistent efforts have resulted in the discovery of Raltegravir (Isentress, MK-0518), the first integrase inhibitor approved by US Food and Drug Administration for the treatment in HIV-1 infected patients. Numerous clinical studies with raltegravir have found it to be safe and effective in treatment naïve as well as treatment experienced patients. Adverse events associated with raltegravir based therapy are milder compared to previously available regimens. Raltegravir is metabolized primarily via glucuronidation mediated by uridine diphosphate glucuronosyltransferase and has a favorable pharmacokinetics independent of age, gender, race, food, and drug-drug interactions. Within a short period of time of its introduction, raltegravir has been included as one of DHHS recommended preferred regimen for the treatment of HIV-1 infection in treatment naïve patients.

Citing Articles

Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.

Kumar A, Loharch S, Kumar S, Ringe R, Parkesh R Comput Struct Biotechnol J. 2021; 19:424-438.

PMID: 33391634 PMC: 7771909. DOI: 10.1016/j.csbj.2020.12.028.

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens.

Ferrer P, Rodriguez C, Sciaraffia A, Tordecilla R, Ramos V, Duran M J Virus Erad. 2020; 6(3):100002.

PMID: 33251020 PMC: 7646669. DOI: 10.1016/j.jve.2020.06.002.

Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.

Gupta A, Guttikar S, Shah P, Solanki G, Shrivastav P, Sanyal M J Pharm Anal. 2018; 5(2):101-109.

PMID: 29403921 PMC: 5761471. DOI: 10.1016/j.jpha.2014.10.002.

Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.

Taylor N, Kremser I, Auer S, Hoermann G, Greil R, Haschke-Becher E J Acquir Immune Defic Syndr. 2016; 75(1):e13-e20.

PMID: 27798431 PMC: 5298192. DOI: 10.1097/QAI.0000000000001223.

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.

Pandey K HIV AIDS (Auckl). 2014; 6:81-90.

PMID: 24876793 PMC: 4037326. DOI: 10.2147/HIV.S39178.

References

Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello A . A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011; 25(12):1481-7. DOI: 10.1097/QAD.0b013e328348dab0. View

Markowitz M, Nguyen B, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C . Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52(3):350-6. DOI: 10.1097/QAI.0b013e3181b064b0. View

Young B, Vanig T, DeJesus E, Hawkins T, St Clair M, Yau L . A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials. 2010; 11(5):260-9. DOI: 10.1310/hct1105-260. View

Lutzke R, Plasterk R . Structure-based mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: critical residues for protein oligomerization and DNA binding. J Virol. 1998; 72(6):4841-8. PMC: 110031. DOI: 10.1128/JVI.72.6.4841-4848.1998. View

Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver L, Parissi V . The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS One. 2010; 5(4):e10311. PMC: 2859942. DOI: 10.1371/journal.pone.0010311. View

Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A . Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011; 365(16):1492-501. PMC: 3233684. DOI: 10.1056/NEJMoa1014181. View

Sichtig N, Sierra S, Kaiser R, Daumer M, Reuter S, Schulter E . Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 2009; 64(1):25-32. DOI: 10.1093/jac/dkp153. View

Rockstroh J, Lennox J, DeJesus E, Saag M, Lazzarin A, Wan H . Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011; 53(8):807-16. DOI: 10.1093/cid/cir510. View

Eron Jr J, Rockstroh J, Reynes J, Andrade-Villanueva J, Ramalho-Madruga J, Bekker L . Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011; 11(12):907-15. DOI: 10.1016/S1473-3099(11)70196-7. View

10.

Lennox J, DeJesus E, Berger D, Lazzarin A, Pollard R, Madruga J . Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55(1):39-48. PMC: 6065510. DOI: 10.1097/QAI.0b013e3181da1287. View

11.

Kulkosky J, Jones K, KATZ R, Mack J, Skalka A . Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol. 1992; 12(5):2331-8. PMC: 364405. DOI: 10.1128/mcb.12.5.2331-2338.1992. View

12.

Engelman A, Hickman A, Craigie R . The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol. 1994; 68(9):5911-7. PMC: 236996. DOI: 10.1128/JVI.68.9.5911-5917.1994. View

13.

Brainard D, Friedman E, Jin B, Breidinger S, Tillan M, Wenning L . Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol. 2010; 51(3):422-7. DOI: 10.1177/0091270010367652. View

14.

Eron J, Young B, Cooper D, Youle M, DeJesus E, Andrade-Villanueva J . Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010; 375(9712):396-407. DOI: 10.1016/S0140-6736(09)62041-9. View

15.

Teppler H, Brown D, Leavitt R, Sklar P, Wan H, Xu X . Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011; 9(1):40-53. PMC: 3267161. DOI: 10.2174/157016211794582650. View

16.

Valkov E, Gupta S, Hare S, Helander A, Roversi P, McClure M . Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 2008; 37(1):243-55. PMC: 2615609. DOI: 10.1093/nar/gkn938. View

17.

Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos C, Charpentier C . Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother. 2009; 53(10):4522-4. PMC: 2764161. DOI: 10.1128/AAC.00651-09. View

18.

Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):355-65. DOI: 10.1056/NEJMoa0708978. View

19.

Hazuda D . Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz J Infect Dis. 2011; 14(5):513-8. View

20.

Hightower K, Wang R, DeAnda F, Johns B, Weaver K, Shen Y . Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011; 55(10):4552-9. PMC: 3187001. DOI: 10.1128/AAC.00157-11. View